Aberrant Proliferation in CXCR7+ Endothelial Cells via Degradation of the Retinoblastoma Protein
Author(s) -
Jennifer Totonchy,
Jessica M. Osborn,
Sara Botto,
Lisa Clepper,
Ashlee V. Moses
Publication year - 2013
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0069828
Subject(s) - retinoblastoma , cancer research , angiogenesis , retinoblastoma protein , tumor microenvironment , endothelium , cell growth , biology , vascular endothelial growth inhibitor , suppressor , microbiology and biotechnology , receptor , vascular endothelial growth factor a , vascular endothelial growth factor , cell , cell cycle , tumor cells , cancer , vegf receptors , endocrinology , genetics , gene
Angiogenesis is a critical factor in the growth and dissemination of solid tumors. Indeed, tumor vasculature is abnormal and contributes to the development and spread of malignancies by creating a hostile microenvironment. The alternative SDF-1/CXCL12 receptor, CXCR7, is frequently and specifically expressed in tumor-associated vessels. In this study, we examine the role of endothelium-expressed CXCR7 in tumor vascular dysfunction by specifically examining the contribution of CXCR7 to endothelial cell (EC) proliferation. We demonstrate that CXCR7 expression is sufficient to drive post-confluent growth in EC cultures. Further, we provide a novel mechanism for CXCR7-mediated proliferation via proteasomal degradation of the tumor suppressor protein Rb. These findings identify a heretofore unappreciated role for CXCR7 in vascular dysfunction and confirm this receptor as a plausible target for anti-tumor therapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom